Jaguar Health Inc. (NASDAQ:JAGX) went down by -6.00% from its latest closing price compared to the recent 1-year high of $13.41. The company’s stock price has collected -18.40% of loss in the last five trading sessions. Press Release reported 15 hours ago that Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
Is It Worth Investing in Jaguar Health Inc. (NASDAQ :JAGX) Right Now?
Plus, the 36-month beta value for JAGX is at 1.55. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Jaguar Health Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $13.50, which is $2.15 above the current price. JAGX currently public float of 40.90M and currently shorts hold a 3.61% ratio of that float. Today, the average trading volume of JAGX was 1.69M shares.
JAGX’s Market Performance
JAGX stocks went down by -18.40% for the week, with a monthly drop of -36.83% and a quarterly performance of -53.92%, while its annual performance rate touched 101.11%. The volatility ratio for the week stands at 10.74% while the volatility levels for the past 30 days are set at 7.24% for Jaguar Health Inc.. The simple moving average for the period of the last 20 days is -29.07% for JAGX stocks with a simple moving average of -53.07% for the last 200 days.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07th of the current year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at -40.17% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.48% of loss for the given period.
Volatility was left at 7.24%, however, over the last 30 days, the volatility rate increased by 10.74%, as shares sank -32.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.46% lower at present.
During the last 5 trading sessions, JAGX fell by -18.40%, which changed the moving average for the period of 200-days by +274.62% in comparison to the 20-day moving average, which settled at $3.26. In addition, Jaguar Health Inc. saw -3.89% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at JAGX starting from BOCHNOWSKI JAMES J, who sale 152 shares at the price of $1.74 back on Jun 04. After this action, BOCHNOWSKI JAMES J now owns 954,390 shares of Jaguar Health Inc., valued at $264 using the latest closing price.
BOCHNOWSKI JAMES J, the Director of Jaguar Health Inc., sale 292 shares at $1.75 during a trade that took place back on Jun 03, which means that BOCHNOWSKI JAMES J is holding 954,542 shares at $511 based on the most recent closing price.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -283.93 for the present operating margin
- +65.05 for the gross margin
The net margin for Jaguar Health Inc. stands at -360.25. The total capital return value is set at -86.59, while invested capital returns managed to touch -133.52. Equity return is now at value -220.40, with -84.20 for asset returns.
Based on Jaguar Health Inc. (JAGX), the company’s capital structure generated 94.23 points at debt to equity in total, while total debt to capital is 48.52. Total debt to assets is 37.84, with long-term debt to equity ratio resting at 72.21. Finally, the long-term debt to capital ratio is 37.18.
When we switch over and look at the enterprise to sales, we see a ratio of 4.22, with the company’s debt to enterprise value settled at 0.41. The receivables turnover for the company is 3.00 and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.